|Assessment Status||Rapid Review complete|
|Indication||Treatment of neovascular (wet) age-related macular degeneration.|
|Rapid review commissioned||26/02/2020|
|Rapid review completed||07/04/2020|
|Rapid review outcome||A full HTA is recommended to assess the clinical and cost effectiveness of brolucizumab compared with the current standard of care.|
The company has not submitted a HTA dossier to the NCPE, therefore the cost effectiveness of the technology could not be proven.